Vascular Embolization Market, By Embolization Technique (Coiling Devices and Non-coiling Devices), By Application (Peripheral Vascular Disease, Oncology, Neurology, Urology, and Other Applications), By Geography (North America, Europe, Asia-Pacific, South America, and Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Published In : Mar 2024

Code : CMI5150

Pages :169

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Recent Developments

In January 2023, Fluidx Medical Technology, Inc., a privately-held medical device company, announced the success of the IMPASS Embolic Device in in-vivo studies of middle meningeal artery (MMA) embolizations, which can be used to treat chronic subdural hematomas (CSDH) on the brain's surface.

In November 2022, Varian, a Siemens Healthineers company, announced that the first trial participant had been treated as part of GENESIS II (Genicular Artery Embolization in Patients with Knee Osteoarthritis), a study of embozene microspheres for genicular artery embolization (GAE) as a treatment for mild to moderate knee osteoarthritis. GENESIS II is GAE's largest randomized clinical trial to evaluate pain alleviation for this chronic illness.

In August 2022, Boston Scientific Corporation, a medical device company, announced the acquisition of Obsidio, Inc., a privately-held company that created Gel Embolic Material (GEM) technology for embolizing blood vessels in the peripheral vasculature. GEM technology, approved by the U.S. Food and Drug Administration (FDA), is a semi-solid, patented material packaged in a ready-to-use form, decreasing the preparation time required for various embolization treatments.

In April 2021, Medtronic plc, a global pioneer in medical technology, gained U.S. FDA approval for its Pipeline Flex Embolization Device with Shield Technology. Medtronic plc developed Shield Technology, a proprietary breakthrough in biomaterial science, to advance flow diversion therapy by introducing the first surface-modified implant device with reduced material thrombogenicity, or the ability of the surface treatment material to form clots. NYU Langone Health in New York City completed the U.S’s first patient procedure with the novel technology.